An 8-week randomised, double-blind, parallel, multiple dose trial comparing NNC0123-0000-0338 in a tablet formulation and insulin glargine in subjects with type 2 diabetes currently treated with oral antidiabetic therapy

Trial Profile

An 8-week randomised, double-blind, parallel, multiple dose trial comparing NNC0123-0000-0338 in a tablet formulation and insulin glargine in subjects with type 2 diabetes currently treated with oral antidiabetic therapy

Completed
Phase of Trial: Phase II

Latest Information Update: 03 Aug 2017

At a glance

  • Drugs Insulin 338 (Primary) ; Insulin glargine
  • Indications Type 2 diabetes mellitus
  • Focus Proof of concept; Therapeutic Use
  • Sponsors Novo Nordisk
  • Most Recent Events

    • 13 Jun 2017 Results presented at the 77th Annual Scientific Sessions of the American Diabetes Association
    • 13 Jun 2017 Primary endpoint has not been met. (Fasting plasma glucose), as per an American Diabetes Association Media Release.
    • 13 Jun 2017 According an American Diabetes Association media release, results from this trial were presented at the American Diabetes Association's 77th Scientific Sessions 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top